News & Press
MindMaze Therapeutics completes reverse merger and prepares for commercial expansion
Edison Group12/15/2025·12/15/25🌐 Europe
Summary
MindMaze became a publicly listed entity through a reverse merger with Relief Therapeutics completed on December 15, 2025. NeuroX shareholders effectively have approximately 90% ownership of the combined entity. The company is targeting over CHF 40 million in FY27 revenue with operating break-even expected in H1 2027.
Why it matters
The reverse merger provides MindMaze with public market access and capital to scale its neurotherapeutics platform. With 1.2 billion data points collected monthly from approximately 35,000 patient users, MindMaze has built a significant dataset for AI-driven neurorehabilitation.
#BCI#Stroke Rehabilitation#Europe#Industry
Want the full NeurotechMag Pro intelligence database?
Access 800+ papers, trials, patents, funding rounds and news items — updated daily.
Start free trialAlready a member? Sign in